GB201120993D0 - Novel compounds and their use in therapy - Google Patents
Novel compounds and their use in therapyInfo
- Publication number
- GB201120993D0 GB201120993D0 GBGB1120993.9A GB201120993A GB201120993D0 GB 201120993 D0 GB201120993 D0 GB 201120993D0 GB 201120993 A GB201120993 A GB 201120993A GB 201120993 D0 GB201120993 D0 GB 201120993D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- therapy
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1120993.9A GB201120993D0 (en) | 2011-12-06 | 2011-12-06 | Novel compounds and their use in therapy |
| PCT/GB2012/053041 WO2013083991A1 (en) | 2011-12-06 | 2012-12-06 | Novel compounds and their use in therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1120993.9A GB201120993D0 (en) | 2011-12-06 | 2011-12-06 | Novel compounds and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201120993D0 true GB201120993D0 (en) | 2012-01-18 |
Family
ID=45541311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1120993.9A Ceased GB201120993D0 (en) | 2011-12-06 | 2011-12-06 | Novel compounds and their use in therapy |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201120993D0 (en) |
| WO (1) | WO2013083991A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX371331B (en) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Dna-pk inhibitors. |
| SI3527563T1 (en) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| DK3424920T3 (en) | 2013-10-17 | 2020-06-08 | Vertex Pharma | CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS |
| CN105315188B (en) * | 2014-06-03 | 2018-10-16 | 武汉药明康德新药开发有限公司 | A kind of preparation method of 2- (1- (tertbutyloxycarbonyl) azelidinyls -3-) ethylene-acetic acid |
| GB201511382D0 (en) * | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| JP2019529475A (en) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of a DNA damaging agent and a DNA-PK inhibitor |
| JP7595413B2 (en) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | Combination of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof - Patents.com |
| CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| KR20250107972A (en) | 2018-05-04 | 2025-07-14 | 레미디 플랜, 인크. | Cancer treatments targeting cancer stem cells |
| CA3120858A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| GB201820659D0 (en) | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Novel compostions and their use in therapy |
| GB201820660D0 (en) | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Cancer treatments |
| JP7458406B2 (en) | 2018-12-21 | 2024-03-29 | セルジーン コーポレーション | Thienopyridine inhibitor of RIPK2 |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| CN114174283B (en) * | 2019-07-18 | 2023-05-12 | 石药集团中奇制药技术(石家庄)有限公司 | Compounds as NMT inhibitors and uses thereof |
| WO2021146370A1 (en) | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| GB202014736D0 (en) | 2020-09-18 | 2020-11-04 | Imperial College Innovations Ltd | Novel compounds and their use in therapy |
| GB202017367D0 (en) | 2020-11-02 | 2020-12-16 | Imperial College Innovations Ltd | Novel use |
| KR20240083168A (en) | 2021-07-14 | 2024-06-11 | 블루프린트 메디신즈 코포레이션 | Heterocyclic compounds as MAP4K1 inhibitors |
| KR20250060207A (en) | 2022-09-09 | 2025-05-07 | 미릭스 파마 리미티드 | Antibody drug conjugates comprising NMT inhibitors and uses thereof |
| EP4644373A1 (en) * | 2022-12-28 | 2025-11-05 | Nippon Soda Co., Ltd. | Hydrazide compound and agricultural/horticultural bactericidal agent |
| GB202403391D0 (en) | 2024-03-08 | 2024-04-24 | Myricx Pharma Ltd | Novel compounds and their use in therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1149094B1 (en) | 1998-12-18 | 2004-04-21 | Basilea Pharmaceutica AG | 4-(aminoalkoxy)benzofurans as n-myristoyltransferase inhibitors |
| US20040014764A1 (en) | 2002-03-29 | 2004-01-22 | Smith Charles D. | N-myristoyltransferase inhibitor compositions and methods of use |
| EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
-
2011
- 2011-12-06 GB GBGB1120993.9A patent/GB201120993D0/en not_active Ceased
-
2012
- 2012-12-06 WO PCT/GB2012/053041 patent/WO2013083991A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013083991A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| EP2739144A4 (en) | Compounds and therapeutic uses thereof | |
| ZA201307797B (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| ZA201403372B (en) | Therapeutic agents and uses thereof | |
| GB201111705D0 (en) | Compounds and their use | |
| IL231082A0 (en) | Pyrimido - pyridazinone compounds and use thereof | |
| PL2780332T3 (en) | Morpholinylbenzotriazines for use in cancer therapy | |
| GB201111630D0 (en) | Novel compounds and their use | |
| GB201218084D0 (en) | Novel compounds and methods for use in medicine | |
| GB201011411D0 (en) | Therapeutic compounds and their use | |
| GB201114448D0 (en) | Compounds and their use | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| IL232809A0 (en) | Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals | |
| GB201102226D0 (en) | Inventions and therapy | |
| GB201102221D0 (en) | Inventions and therapy | |
| GB201102215D0 (en) | Inventions and therapy | |
| GB201102232D0 (en) | Inventions and therapy | |
| GB201102234D0 (en) | Inventions and therapy | |
| GB201102213D0 (en) | Inventions and therapy | |
| GB201102239D0 (en) | Inventions and therapy | |
| GB201102231D0 (en) | Inventions and therapy | |
| GB201102227D0 (en) | Inventions and therapy | |
| GB201102228D0 (en) | Inventions and therapy | |
| GB201102222D0 (en) | Inventions and therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |